A medicine for treating rheumatoid arthritis and uses thereof

A technology for arthritis and rheumatoid arthritis, which is applied in the field of drugs for the treatment of rheumatoid arthritis, and can solve the problems of lack of safe and effective drugs, difficult treatment, failure of secondary treatment, etc.

Inactive Publication Date: 2019-01-15
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of RA is very difficult, so far, there is still a lack of safe and effective therapeutic drugs
Modern medicine is mainly about anti-inflammation and reducing sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients. Its non-response, or the failure of the second treatment, an average of about 10% of patients discontinued each year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A medicine for treating rheumatoid arthritis and uses thereof
  • A medicine for treating rheumatoid arthritis and uses thereof
  • A medicine for treating rheumatoid arthritis and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0020] The CIA model of DBA / 1 mice was established. DBA / 1 female mice for 6-8 weeks, after adaptive feeding for 1 week, use bovine type II collagen (2mg / mL) and complete Freund's adjuvant (BCG concentration is 4mg / ml), after complete emulsification, inject 100μL of the tail subcutaneously (containing 100μg bovine type II collagen), and 21 days later, the second immunization was carried out, using bovine type II collagen (2mg / mL) and incomplete Freund's adjuvant, after complete emulsification, 100μL (containing 100μg bovine type II collagen) was subcutaneously injected into the tail . After the second immunization of DBA / 1 mice on the first day (D20), the model mice were randomly divided into groups, i.e. ascarin group and model group, with more than 10 mice in each group. In the asiaticoside group, asiaticoside was dissolved in 0.5% sodium carboxymethylcellulose (CMC-Na) to prepare a suspension, and in the model group, 0.5% CMC-Na was used. The dosage of ascarin is 40mg / kg. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is astragalin, and the effective concentration is 10-1000 [mu]M. The astragalin is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As proved by animal experiments, the astragalin can reduce clinical symptom score and synovial fluid volume of mice with collagen-induced rheumatoid arthritis, inhibit expression of matrix metalloproteinase of human synoviocytes induced by TNF alpha, and effectively improve rheumatoid arthritis symptom. The invention also relates to the use of astragalin in the preparation of medicine or health product for preventingand treating rheumatoid arthritis. The effective concentration of astragalin is 10-1000 [mu]M.

Description

technical field [0001] The invention relates to a medicine for treating rheumatoid arthritis, and proposes the application of the medicine in preparing various forms of medicines or health food for preventing and treating rheumatoid arthritis. Background technique [0002] The prior art discloses that rheumatoid arthritis (Rheumatoid Arthritis, RA) is a chronic, systemic, progressive, autoimmune disease characterized by extensive persistent joint synovitis and symmetrical, destructive joint lesions as a feature. The treatment of RA is very difficult, so far, there is still a lack of safe and effective drugs. Modern medicine is mainly about anti-inflammation and alleviating sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients, but many patients still have problems in initial treatment. Its non-response, or the failure of the second treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P19/02
CPCA23L33/105A23V2002/00A61K31/7048A23V2250/21A23V2200/30
Inventor 梁倩倩王拥军徐浩施杞贾庆运王晓赟陈锦漫陈涛王腾腾王琼刘洋王怡茹许崇卿刘利齐晓凤赵永见李强
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap